STERIS (NYSE:STE) Sets New 12-Month Low - What's Next?

Key Points

• Shares of STERIS hit a new 52-week low of $209.61 (last $212.99) on Tuesday, trading below both the 50‑day ($226.36) and 200‑day ($244.80) moving averages, indicating near‑term technical weakness.
• Analysts have trimmed ratings recently (e.g., Wall Street Zen to Buy, Weiss to Hold), but the consensus remains a Moderate Buy with an average price target of $275.20.
• On fundamentals, STERIS reported Q results that met EPS estimates ($2.53) with revenue up 9.2% and set FY2026 guidance of 10.15–10.30 EPS, essentially in line with the sell‑side forecast of 10.22.

Shares of STERIS plc (NYSE:STE - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $209.61 and last traded at $212.99, with a volume of 69494 shares trading hands. The stock had previously closed at $212.25.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on STE shares. Wall Street Zen cut shares of STERIS from a "strong-buy" rating to a "buy" rating in a research report on Sunday, April 26th. Weiss Ratings cut shares of STERIS from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, April 16th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.20.

STERIS Price Performance

The business's 50 day moving average price is $226.36 and its two-hundred day moving average price is $244.80. The stock has a market cap of $20.90 billion, a P/E ratio of 29.71 and a beta of 0.95. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts' consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. STERIS's revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the business posted $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, sell-side analysts expect that STERIS plc will post 10.22 earnings per share for the current fiscal year.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares of the company's stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.07% of the company's stock.

Institutional Investors Weigh In On STERIS

Large investors have recently modified their holdings of the stock. Nordea Investment Management AB boosted its stake in STERIS by 259.0% during the fourth quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider's stock worth $13,165,000 after acquiring an additional 37,228 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in STERIS by 9.4% during the third quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider's stock worth $257,157,000 after acquiring an additional 89,250 shares in the last quarter. Asset Management One Co. Ltd. boosted its stake in STERIS by 5.4% during the third quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider's stock worth $24,366,000 after acquiring an additional 5,072 shares in the last quarter. Legal & General Group Plc boosted its stake in STERIS by 5.3% during the third quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider's stock worth $171,505,000 after acquiring an additional 34,981 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in STERIS during the third quarter worth about $1,163,000. Institutional investors own 94.69% of the company's stock.

STERIS Company Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.